Articles & Video
Allogeneic and Autologous Cell Therapies Report 2022
The results of our study reveals emerging trends in the allogeneic and autologous cell therapy space.
Commercialization of Cell & Gene Therapies
This ebook presents insights from industry leaders, including partnering strategies, process technologies and control considerations.
COVID hit cell and gene therapy trials and suppliers but experts see signs of recovery
COVID-19 disrupted cell and gene therapy trials as well as the contractors and suppliers that support them, according to experts.
Advancing Gene Therapies: Evaluating Immunogenicity and its Impact on Therapeutic Potential
What are the considerations for selecting the best immunogenicity assay?
Survey: Cell & Gene Therapy COVID-19 Response
What changes are happening in the cell and gene therapy sector as a result of the pandemic? Tell us your experience.
Ebook: The Future of the Cell and Gene Therapy Industry
What can we expect next from the cell and gene therapy sector? This ebook explores the potential paths ahead, from optimized CAR-T to automated bioprocessing.
Viral vectors have biggest limitations in vector manufacturing, according to industry survey
Exploring results of our industry survey, we identify the biggest pain points in vector manufacturing experienced by cell and gene therapy professionals.
Vector manufacturing for cell and gene therapies: how should current platforms be changed?
What do we need from vector manufacturing platforms to deliver commercial scale therapies? We look at responses from industry insiders.
Novel analytical strategies and tools for cell and gene therapies - WHITEPAPER
What analytical techniques can be applied to production of cell therapies, gene therapies and gene-edited cell-therapies? This whitepaper looks at the latest examples.
Automating cell and gene therapy manufacturing: challenges and approaches
With the pressure on to scale up manufacturing of cell and gene therapies, what steps should organizations take to optimize their processes with automation? We asked three industry experts for their advice.
Cell and Gene Therapy Report 2020: Viral and Non-viral Vectors
This report of our recent global industry survey reveals the biggest challenges in viral and non-viral vector manufacturing for cell and gene therapies.
Gene-Edited Cell Therapies: CMC Challenges and Considerations - WHITEPAPER
This whitepaper reviews the current challenges in manufacturing gene-edited cell therapies and ways to approach them, presenting key case studies.
Technologies and Novel Platforms for Optimizing Cell and Gene Therapies
This interactive ebook explores the unique challenges in the cell and gene therapy industry which are being solved by emerging technology and platforms.
BioProcess International Spring Digital Week 2020 agenda revealed
We reveal the sessions of the upcoming 7-day webinar series on innovating biopharmaceutical development and production.
Why gene therapy lotteries are good for patients, providers, and manufacturers
Jeremy Schafer, PharmD, MBA argues how drug lotteries like Novartis' new program could mean a fairer and more beneficial system for all.
Does Zolgensma’s success predict similar rapid uptake of gene therapy for Hemophilia?
Doe the success of Zolgensma mean payers will be as welcoming to the cost and volume of hemophilia gene therapy or will payers wait for competition?
Measure Twice, Treat Once: Navigating the regulatory landscape of assay development to ensure high-quality CGT products
In this article from BioProcess International, the authors discuss the use of analytical assays in process development and manufacturing of cell and gene therapeutics.
Engineering strategies for TCR and CAR-T cell therapies - WHITEPAPER
Engineering strategies for TCR and CAR-T cell therapies - download this whitepaper exploring the latest developments.
Autologous cell therapies: Commercialization strategies
This BioProcess International eBook looks at commercialization strategies for autologous cell therapies.
Insourcing vs outsourcing in cell and gene therapy manufacturing - WHITEPAPER
This whitepaper presents best practices for planning an outsourcing or insourcing strategy for manufacturing cell and gene therapies.
Bioprinting capabilities and futures
Bioprinting is ready to create tissue products with high commercial and therapeutic value, but there are still key development hurdles to make this technology viable.